

Dated: June 1, 2007.

**Bryant L. VanBrakle**,  
Secretary.

[FR Doc. E7-10896 Filed 6-5-07; 8:45 am]

BILLING CODE 6730-01-P

## FEDERAL MARITIME COMMISSION

### Ocean Transportation Intermediary License Applicants

Notice is hereby given that the following applicants have filed with the Federal Maritime Commission an application for license as a Non-Vessel-Operating Common Carrier and Ocean Freight Forwarder-Ocean Transportation Intermediary pursuant to section 19 of the Shipping Act of 1984 as amended (46 U.S.C. Chapter 409 and 46 CFR part 515).

Persons knowing of any reason why the following applicants should not receive a license are requested to contact the Office of Transportation Intermediaries, Federal Maritime Commission, Washington, DC 20573.

### Non-Vessel-Operating Common Carrier Ocean Transportation Intermediary Applicants

CNF International, Inc., 550 E. Carson Plaza Drive, #112, Carson, CA 90746.  
*Officers:* Paul Wang Lee, President (Qualifying Individual), Mi Ran Lee, Secretary.

Evangel Shipping, Inc., 10408 Daines Drive, Temple City, CA 91780.  
*Officer:* Xiujuan Lai, CEO (Qualifying Individual).

Champ International Shipping, Inc., 900 Kaighns Avenue, Camden, NJ 08104.  
*Officer:* Roy Barrington Hibbert, President (Qualifying Individual).

Cargois Inc., 2700 Coyle Avenue, Elk Grove Village, IL 60007. *Officers:* Souck-Sin Lee, Treasurer (Qualifying Individual), Jong Han Kwon, President.

Best Shipping Ever, Inc., 734 Grand Avenue, Unit C, Ridgefield, NJ 07657.  
*Officer:* Young S. Kim, President, (Qualifying Individual).

Golden Sea USA Inc., 155-06 So. Conduit Ave., Suite 200, Jamaica, NY 11434. *Officers:* Zhang, Shen, Vice President, (Qualifying Individual), Xia Fang, President.

Dyna Logistics Inc., 2415 S. Sequoia Drive, Compton, CA 90220. *Officers:* Alfie Chi-Yang, Director (Qualifying Individual), Michelle Yang, Director/Secretary.

Siboney Shipping LLC, 10943 NW 122 Street, Medley, FL 33178. *Officer:* Kaye Graham, Owner (Qualifying Individual).

### Non-Vessel-Operating Common Carrier and Ocean Freight Forwarder Transportation Intermediary Applicants

AHC Logistics Cargo Consultant, Inc., 11591 NW 50th Terrace, Doral, FL 33178. *Officers:* Alberto Jose Hernandez Crassus, President (Qualifying Individual), Amy Aracely Vega, Vice President.

Express International Cargo, Corp., dba Express Ocean Services, 7220 NW 36 Street, Suite 300, Miami, FL 33166.  
*Officer:* Carlos Adolfo Marzol, President (Qualifying Individual).

Salviati and Santori Enterprises Inc., 10 East Merrick Road, Suite 200, Valley Stream, NY 11580. *Officers:* Richard Cazan-Cassini, Exec. Vice Pres. (Qualifying Individual), Francesco Santori, President.

IPPCO Global Services, Inc., 14589 Industry Circle, La Mirada, CA 90637.  
*Officers:* John W. Gamble, III, Secretary (Qualifying Individual), Dina T. Gamble, President.

Advanced Maritime Transports, Inc. dba AMT, 16800 Greenspoint Park Drive, Suite 170N, Houston, TX 77030.  
*Officers:* William E. Netzing, III, President (Qualifying Individual), Alain Vedrines, Director.

Dated: June 1, 2007.

**Bryant L. VanBrakle**,  
Secretary.

[FR Doc. E7-10899 Filed 6-5-07; 8:45 am]

BILLING CODE 6730-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### National Center for Environmental Health/Agency for Toxic Substance and Disease Registry; The Health Department Subcommittee of the Board of Scientific Counselors, CDC, National Center for Environmental Health (NCEH)/Agency for Toxic Substances and Disease Registry (ATSDR): Teleconference Meeting

*Notice of Cancellation:* This notice was published in the **Federal Register** on May 4, 2007, Volume 72, Number 86, page 25318. The meeting previously scheduled to convene on June 4, 2007 has been cancelled.

*Contact Person for More Information:* Shirley D. Little, Committee Management Specialist, NCEH/ATSDR, 1600 Clifton Road, Mail Stop E-28, Atlanta, GA 30303; telephone 404/498-0615, fax 404/498-0059; E-mail: [slittle@cdc.gov](mailto:slittle@cdc.gov).

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: May 30, 2007.

**Elaine L. Baker**,

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E7-10880 Filed 6-5-07; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 2000E-1253]

#### Determination of Regulatory Review Period for Purposes of Patent Extension; RAPLON

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) has determined the regulatory review period for RAPLON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

**ADDRESSES:** Submit written comments and petitions to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.fda.gov/dockets/eccomments>.

**FOR FURTHER INFORMATION CONTACT:** Beverly Friedman, Office of Regulatory Policy (HFD-007), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

**SUPPLEMENTARY INFORMATION:** The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period